High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
about
Safety of intravenous iron use in chronic kidney disease.A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemiaThe NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency.A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.Intravenous Irons: From Basic Science to Clinical Practice
P2860
High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High-dose fast infusion of par ...... r fibroblast growth factor 23.
@en
High-dose fast infusion of par ...... r fibroblast growth factor 23.
@nl
type
label
High-dose fast infusion of par ...... r fibroblast growth factor 23.
@en
High-dose fast infusion of par ...... r fibroblast growth factor 23.
@nl
prefLabel
High-dose fast infusion of par ...... r fibroblast growth factor 23.
@en
High-dose fast infusion of par ...... r fibroblast growth factor 23.
@nl
P2093
P2860
P1476
High-dose fast infusion of par ...... r fibroblast growth factor 23.
@en
P2093
Bent A Jacobsen
Janneke van der Woude
Lars L Thomsen
Lars-Åke Bark
Stefan Lindgren
P2860
P304
P356
10.1080/00365521.2016.1196496
P577
2016-06-21T00:00:00Z